Clinical trials: Inhibition
HIV Infections
PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection
Background: HIV affects millions of people. The disease may "hide" in the brain, even in people with well-controlled HIV without cancer. Then it may "wake up" and continue.
- Trial name
- NCT03239899
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Ovarian Cancer, Fallopian Tube Cancer
European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer
This study will be performed in women with platinum-sensitive, high-grade serous, high-grade endometrioid, undifferentiated epithelial ovarian cancer, carcinosarcoma, fallopian tube or primary peritoneal cancer (proven by central…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- EUDARIO (NCT03783949)
- Testing
- Ganetespib, Niraparib, Carboplatin
- Where
- 13 sites in Austria, Belgium and 3 more
- Volunteers
- 122 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
FSGS, MCD
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
Adalimumab, a treatment which blocks tumor necrosis factor (TNF), was tested to see if it changed levels of urine biomarker levels, tissue inhibitor of metalloprotease-1 (TIMP1), and monocyte chemoattractant protein-1 (MCP1).
- Conditions
- FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Trial name
- NCT04009668
- Testing
- adalimumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Prostate Cancer
PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer
The purpose of this study is to assess the safety and efficacy of avelumab in patients with metastatic neuroendocrine-like prostate cancer.
- Trial name
- PICK-NEPC (NCT03179410)
- Testing
- Avelumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Andrew J. Armstrong, MD
Atopic Dermatitis Eczema
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
This was a Phase 3, 4-week, double-blind study to assess the safety and efficacy of ARQ-151 cream compared to vehicle cream applied once daily (qd) for 4 weeks in children 2 to 5 years of age with atopic dermatitis (AD).
- Trial name
- NCT04845620
- Testing
- Roflumilast Cream 0.05%, Vehicle Cream
- Where
- 76 sites in United States, Canada
- Volunteers
- 652 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Sarcoidosis
Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes
The study hypothesizes that inhibition of the receptor CCR5 by maraviroc will diminish inflammation in patients with sarcoidosis.
- Trial name
- GRADS (NCT02134717)
- Testing
- all subjects will receive maraviroc 300mg orally twice a day for 6 weeks, Bronchoscopy with bronchoalveolar lavage, venipunctures
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Kevin F. Gibson
HIV Infections
MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection
The purpose of this research study is to see if HIV that persists despite current antiviral therapy can be targeted by new treatments.
- Trial name
- NCT00614458
- Testing
- Raltegravir; valproic acid
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of North Carolina, Chapel Hill
Prostate Cancer
Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies
This is a single center prospective imaging study investigating the utility of hyperpolarized C-13 pyruvate as a Biomarker of PI3K/mTOR pathway inhibition in patients with advanced solid tumor malignancies.
- Trial name
- NCT02913131
- Testing
- Pyruvate (13C), MRI
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Rahul Aggarwal
Heart Failure
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2
LCZ696, a molecular complex of the angiotensin receptor blocker (ARB) valsartan with an inhibitor of neprilysin (NEP, neutral endopeptidase-24.11) sacubitril improved mortality compared to enalapril in patients with heart failure…
- Trial name
- NCT04113109
- Testing
- LCZ 696, Icatibant, Para-aminohippurate
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Vanderbilt University Medical Center
Thrombocytopenia, Alloimmune Platelet Refractoriness
Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
Background: Platelets are tiny cells in the blood that help stop bleeding. Thrombocytopenia happens when people do not have enough normal platelets.
- Trial name
- NCT02298933
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Stage IV Melanoma, Metastatic Melanoma
Immunotherapy Study for Patients With Stage IV Melanoma
The purpose of this study is to examine the effectiveness of immune checkpoint inhibitors (drugs called ipilimumab, nivolumab, or pembrolizumab), either given alone, or in combination with the experimental immunotherapy drug…
- Trial name
- NCT02054520
- Testing
- HyperAcute®-Melanoma (HAM) Immunotherapy, Ipilimumab, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- NewLink Genetics Corporation
Emphysema
Prostaglandin Inhibition for Emphysema
The Prostaglandin Inhibition for Emphysema (PIE) study will determine if a currently available therapy, ibuprofen 600 mg three times daily, can block PGE production in the lower respiratory tract and if this results in…
- Trial name
- PIE (NCT02006576)
- Testing
- 600 mg ibuprofen three times daily for 48 weeks
- Where
- 5 sites in United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Diabetes Mellitus, Type 2, Coronary Artery Disease
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
The purpose of this study is to determine whether bromodomain extraterminal domain (BET) inhibition treatment with RVX000222 in high-risk type 2 diabetes mellitus patients with coronary artery disease increases the time to major…
- Trial name
- BETonMACE (NCT02586155)
- Testing
- Apabetalone, Atorvastatin, Rosuvastatin
- Where
- 214 sites in Argentina, Australia and 13 more
- Volunteers
- 2,425 people
- Sponsor
- Resverlogix Corp
Aortic Stenosis
Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study
Currently, aortic stenosis (AS) is considered a "surgical disease" with no medical therapy available to improve any clinical outcomes, including symptoms, time to surgery, or long-term survival.
- Trial name
- ASPEN-AVR (NCT01272388)
- Testing
- Tadalafil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Washington University School of Medicine
Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer
The SABR-ATAC trial (Stereotactic Ablative Radiotherapy and anti-TGFB Antibody Combination) is a phase I/II trial that studies the side effects and efficacy of fresolimumab, an anti-transforming growth factor beta (TGFB)…
- Trial name
- NCT02581787
- Testing
- Fresolimumab, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Maximilian Diehn
Coronary Artery Disease
The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial (PACIFY)
With potent analgesic properties, perceived hemodynamic benefits and limited alternatives, opiates are the analgesic mainstay for acute coronary syndrome (ACS) patients reporting peri-procedural pain or nitrate-resistant chest…
- Trial name
- PACIFY (NCT02683707)
- Testing
- Removal of Fentanyl from peri-procedural analgesia, Fentanyl, Lidocaine
- Where
- United States
- Volunteers
- 212 people
- Sponsor
- Johns Hopkins University
Myocardial Ischemia, Acute Coronary Syndrome
EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)
The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention…
- Trial name
- NCT00089895
- Testing
- Eptifibatide (Integrilin)
- Volunteers
- 9,406 people
- Sponsor
- Organon and Co
Lymphangioleiomyomatosis (LAM)
COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
The investigators will perform a two-center phase I trial of celecoxib (COX-2 inhibitor) administered at 200mg by mouth daily for 6 months. Up to 12 adult women with LAM will be recruited (between 4-8 at each site).
- Trial name
- COLA (NCT02484664)
- Testing
- Celecoxib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure, Type 2 Diabetes Mellitus
SGLT2 Inhibition in Combination With Diuretics in Heart Failure
The RECEDE-CHF trial is a single centre phase IV, randomised, double-blind, placebo-controlled, crossover trial conducted in NHS Tayside, Scotland comparing empagliflozin 25mg, to placebo in patients with Type 2 Diabetes and mild…
- Trial name
- RECEDE-CHF (NCT03226457)
- Testing
- Empagliflozin 25mg, Frusemide
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- University of Dundee
Heart Failure
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Diastolic heart failure (DHF), which affects older individuals and women at a disproportionate rate, is a condition that can lead to shortness of breath and fluid build-up in the lungs.
- Trial name
- RELAX (NCT00763867)
- Testing
- Sildenafil
- Where
- 10 sites in United States, Canada
- Volunteers
- 216 people
- Sponsor
- Duke University